<DOC>
	<DOCNO>NCT00000997</DOCNO>
	<brief_summary>To determine much dose absorbed body zalcitabine ( dideoxycytidine ; ddC ) give orally long drug stay body absorption intravenous ( IV ) administration . Laboratory test show ddC effective stopping growth HIV test tube . The study reveal pharmacokinetic ( blood level ) property new drug long drug remain body six dos . This useful background information allow simple efficient comparative study new oral formulation , tablet capsule , since dose-related problem already know .</brief_summary>
	<brief_title>A Study Dideoxycytidine HIV-Infected Patients</brief_title>
	<detailed_description>Laboratory test show ddC effective stopping growth HIV test tube . The study reveal pharmacokinetic ( blood level ) property new drug long drug remain body six dos . This useful background information allow simple efficient comparative study new oral formulation , tablet capsule , since dose-related problem already know . Patients hospitalize receive ddC twice , mouth IV injection . Each patient receive drug one six increase dos , patient study one dose level . Following dose , toxicity measure next high dose give . Several blood sample urine specimen take permit measurement amount drug bloodstream speed eliminate body .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<criteria>Inclusion Criteria Prior Medication : Allowed : Oral nonabsorbable antifungal agent . Exclusion Criteria Active drug alcohol abuse . Coexisting Condition : Patients fever &gt; 102 degree F study entry exclude . Patients fever &gt; 102 degree F study entry exclude . Prior Medication : Excluded : Chronic systemic medication . Any experimental drug within 2 week study entry . Drugs known nephrotoxic hepatotoxic effect within 2 week study entry . Drugs know cause neutropenia within 2 week study entry . Rifampin rifampin derivative , phenytoin , barbiturates within 2 week study entry . Any medication except oral nonabsorbable antifungal agent within 72 hour study entry . All medication , include aspirin , must approve investigator . All medication , include aspirin , must approve investigator . Patients must demonstrate follow clinical laboratory finding : AIDS , AIDS relate complex ( ARC ) , persistent generalize lymphadenopathy define CDC classification . No ascites . Off medication except oral antifungal , nonabsorbable agent 72 hour prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Biological Availability</keyword>
</DOC>